Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Helios Underwriting executive chair to step down

(Sharecast News) - Lloyds of London investor Helios Underwriting, which is currently searching for a new CEO, has announced that executive chair Michael Wade is to also leave the company at the end of the month. The company, which is the only publicly traded company with a portfolio of syndicates at Lloyd's, said that Wade - who only joined in June 2023 as non-executive chair - has decided to step down from his role "to continue developing his non-executive portfolio".

The news comes in the aftermath of June's resignation of chief executive Martin Reith who stepped down to pursue other opportunities, at which point Wade took over as executive chair.

During this tenure, Wade has guided Helios through a period of change and strong performance, overseeing a portfolio restructuring, materially reducing underwriting risk, gearing and overall cost base for 2025, the company said.

Most recently as Executive Chairman, he oversaw the Group's portfolio restructuring, materially reducing the Company's underwriting risk, gearing and overall cost base for 2025. These strategic priorities will remain unchanged under John Chambers.

"On behalf of the board, I thank Michael for his leadership and he leaves with our best wishes. He has played a key role in Helios' strong growth and successful restructuring, leaving the business well positioned for the future," said John Chambers, the non-executive director who has been named as Wade's interim replacement.

"As we look ahead, I look forward to undertaking a search for a new chief executive officer. Helios remains committed to its long term strategy of selecting the best-performing syndicates at Lloyd's to maximise returns for investors."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.